Based on the Agenus Inc stock forecast from 3 analysts, the average analyst target price for Agenus Inc is USD 7.80 over the next 12 months. Agenus Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Agenus Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Agenus Inc’s stock price was USD 1.70. Agenus Inc’s stock price has changed by +8.97% over the past week, -17.07% over the past month and -79.14% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for Agenus Inc
No recent average analyst rating found for Agenus Inc
Company Overview Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Read Less
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification o...Read More
Frequently Asked Questions About Agenus Inc (AGEN) Stock
Based on ratings from 3 analysts Agenus Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on AGEN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AGEN is USD 7.80 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 3.
AGEN stock's Price/Earning ratio is 0.46.
Our analysis grades AGEN stock's Price / Earning ratio at C+. This means that AGEN stock's Price/Earning ratio is above 23% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AGEN may be undervalued for its sector.
The last closing price of AGEN's stock was USD 1.70.
The most recent market capitalization for AGEN is USD 0.04B.
Based on targets from 3 analysts, the average taret price for AGEN is projected at USD 7.80 over the next 12 months.
This means that AGEN's stock price may go up by +358.82% over the next 12 months.
We can't find any ETFs which contains Agenus Inc's stock.
As per our most recent records Agenus Inc has 316 Employees.
Agenus Inc's registered address is 3 Forbes Road, Lexington, MA, United States, 02421-7305.
You can get more information about it from Agenus Inc's website at https://www.agenusbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Agenus Inc (AGEN) Stock
Based on ratings from 3 analysts Agenus Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on AGEN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for AGEN is USD 7.80 over the next 12 months. The maximum analyst target price is USD 11 while the minimum anlayst target price is USD 3.
AGEN stock's Price/Earning ratio is 0.46.
Our analysis grades AGEN stock's Price / Earning ratio at C+. This means that AGEN stock's Price/Earning ratio is above 23% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AGEN may be undervalued for its sector.
The last closing price of AGEN's stock was USD 1.70.
The most recent market capitalization for AGEN is USD 0.04B.
Based on targets from 3 analysts, the average taret price for AGEN is projected at USD 7.80 over the next 12 months.
This means that AGEN's stock price may go up by +358.82% over the next 12 months.
We can't find any ETFs which contains Agenus Inc's stock.
As per our most recent records Agenus Inc has 316 Employees.
Agenus Inc's registered address is 3 Forbes Road, Lexington, MA, United States, 02421-7305.
You can get more information about it from Agenus Inc's website at https://www.agenusbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AGEN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
